SALEM, N.H., June 6 /PRNewswire/ -- The makers of the WaveSense(TM) line of blood glucose monitoring products (AgaMatrix, Inc.) announce the launch of the WaveSense Presto and WaveSense KeyNote Pro Blood Glucose Monitoring Systems (BGMS). The Presto is a no code meter with premium features that consumers can buy at a value price. The Pro is designed for use in institutional settings with added features for increased safety.
The Presto has all the market-leading features of AgaMatrix's first product, the WaveSense KeyNote(R), but does not require coding and is priced considerably less than no code products from the major brands. The system also has improved ergonomics and a brighter backlit display. Like the KeyNote, it requires a small sample size (0.5 microliters), is As Fast As 1-2-3(R), and has alternate site testing. Presto builds on the existing base of WaveSense customers that is expected to exceed 1,000,000 by this fall.
"We are extremely excited to launch our first no code product in the United States," said Dave Conn, Chief Commercial Officer. "Following the feedback we received from our users, the new Presto meets a growing market need for an affordable system that also has high accuracy and is easy to use. We are very proud of our progress and these new products are an important transition for our company as we grow. Consumers will be able to find the Presto in retail outlets this fall."
In a recent clinical study, the Presto was shown to be extremely accurate, as 93% of the results were within 10% of a lab standard*.
The WaveSense product portfolio consists of the KeyNote and KeyNote Pro, for users who want a value meter, the Presto, for users who want a no code meter, and the WaveSense Jazz(TM), for users who want a premium meter for better control. All products uniquely feature WaveSense, a new technology that personalizes each test to provide world class accuracy.
Marian Batts-Turner, MSN, RN, CDE, a leading diabetes educator who is a faculty member of the Welch Center for Prevention, Epidemiology, and Clinical Research, at Johns Hopkins University, said, "It's great to see that the company is listening to what diabetes educators and patients are asking for -- high accuracy systems that are more affordable and easier to use. This is vital for improving patient care."
WaveSense is a line of products designed to improve the quality of diabetes care by using a new technology that personalizes each test to provide world class accuracy. It detects and corrects for many errors caused by differences in blood samples and environmental conditions. The company also makes Zero-Click(TM), a diabetes data management system designed to simplify data download. Together there are six FDA-cleared products protected by a suite of more than 160 patents worldwide. For more information on or to buy WaveSense products, see http://www.wavesense.info.
* Based on an ISO 15197 system accuracy study; Type 1 & Type 2 participants, YSI reference. Result is for reference concentrations greater than or equal to 75 mg/dL. Laboratory Standard is a Yellow Springs Instrument (YSI) 2300 STAT Plus Blood Glucose Analyzer.
WaveSense; Presto; Pro; KeyNote; WaveSense Jazz; and Zero-Click are trademarks of AgaMatrix, Inc.
Copyright©2008 PR Newswire.
All rights reserved